ArticleBMC nephrology2026
Patency of arteriovenous fistulas in hemodialysis in French Guiana: influence of vascular flow, climate and clinical factors.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionArteriovenous fistula (AVF) is the preferred access for hemodialysis. Achieving one-year patency is crucial to avoid dependence on central venous catheters, which carry significant risks of infection and thrombosis. In French Guiana, a territory marked by precariousness, isolation, and a tropical climate, local determinants of patency are poorly documented. This study aims to evaluate AVF patency at 6 weeks and one year and to identify associated factors.
methodsThis is a single-center retrospective study including all AVFs created at the Cayenne Hospital Center between 2018 and 2022. Demographic data, comorbidities, vascular parameters, technical characteristics, and season were analyzed. Associations were studied using univariate and multivariate logistic regressions with a multilevel model. The primary endpoint was AVF patency at 6 weeks and 1 year.
resultsAmong 176 patients, 226 AVFs were created, 92.5% of which were autologous. Patency at one year was 73.7%. Obesity (Body Mass Index ≥ 30) was associated with reduced patency at one year (OR = 0.46; 95% CI [0.24–0.85], p = 0.014) but not at 6 weeks while active smoking reduced patency at one year (OR = 0.34; [0.13–0.89], p = 0.029) but not at 6 weeks. Each previous AVF also reduced the probability of patency (OR = 0.45; [0.27–0.75], p = 0.002 at 6 weeks; OR = 0.54; [0.35–0.84], p = 0.006 at one year). Conversely, a higher mean initial arterial flow significantly improved patency (OR = 3.31; [1.22–8.92], p = 0.018); high flow had an even more pronounced effect (OR = 6.32; [1.63–24.6], p = 0.008); a larger radial diameter was also associated with better outcomes (OR = 2.42; [1.45–4.05], p = 0.001). A season × flow interaction suggested increased vulnerability of AVFs at low flow during the wet season (OR = 0.15; [0.02–1.04], p = 0.05).
conclusionsIn French Guiana, AVF patency at one year is primarily determined by vascular parameters (arterial flow and diameter). Modifiable risk factors including obesity and active smoking significantly reduce patency, while multiple previous AVF attempts predict worse outcomes. Exploratory analysis suggests possible seasonal vulnerability in low-flow fistulas, requiring prospective vascular assessment, risk factor optimization, and targeted protocols. STUDY REGISTRATION: Not applicable. This is a retrospective observational cohort study. Trial registration is not required for observational studies according to ICMJE and BMC guidelines. The study was not registered prospectively.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.